Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Kronos parlays diverse pipeline into $105M series A

The speed at which Kronos assembled a broad small molecule platform against hard-to-target hormone receptors, transcription factors and E3 ligases enabled it to raise a $105 million A round led by seed investors Vida Ventures and Omega Funds -- more than twice the amount the company originally sought.

President and CEO Norbert Bischofberger told BioCentury the round will give Kronos Bio Inc. (San Mateo, Calif.) runway for at least two years, during which

Read the full 727 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers